LONDON - Tissue Regenix Group plc, a regenerative medical devices company, has established a secondary market trading facility through Asset Match following its delisting from London’s AIM market, ...

The market offers explosive potential as biology transitions to factory-scale production. Anchored by the USD 100 genome and ...